IP Library Assignment 043214/0671
Patent Assignment
Reel/Frame 043214/0671

Security Interest

Recorded: 2017-08-07 Pages: 14
Assignors
ONCOLIX, INC.
Executed: 2017-08-03
Assignee
PURITAN PARTNERS LLC
369 LEXINGTON AVE., 25TH FLOOR, C/O CENTRECOURT ASSET MANAGEMENT LLC, NEW YORK, NEW YORK, 10017
Covered Properties (8)
Bi-Functional Cancer Treatment Agents
Patent: 7,201,905 →
Application: 09/815,306 →
Publication: US 2002/0068043
Use of Anti-Prolactin Agents to Treat Proliferative Conditions
Patent: 7,115,556 →
Application: 10/140,293 →
Publication: US 2003/0022833
Multimeric Ligands with Enhanced Stability
Patent: 7,632,809 →
Application: 10/419,976 →
Publication: US 2004/0033948
Human Prolactin Antagonist-Angiogensis Inhibitor Fusion Proteins
Patent: 7,339,027 →
Application: 10/449,609 →
Publication: US 2004/0127407
Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
Patent: 8,754,031 →
Application: 11/073,927 →
Publication: US 2005/0271626
Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins
Patent: 8,304,381 →
Application: 12/010,395 →
Publication: US 2009/0088375
Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells
Patent: 8,754,035 →
Application: 12/706,702 →
Publication: US 2010/0215577
Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells
Patent: 8,648,046 →
Application: 12/948,329 →
Publication: US 2011/0065639
Related Assignments (3)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Nov 1, 2011
From: CHEN, WEN Y.
To: ONCOLIX, INC.
Reel/Frame 027152/0814 →
Assignment of Assignor's Interest Jul 26, 2017
From: CHEN, WEN Y.
To: ONCOLIX, INC.
Reel/Frame 043105/0402 →
Security Interest May 27, 2018
From: ONCOLIX, INC.
To: PURITAN PARTNERS LLC (AGENT)
Reel/Frame 045908/0481 →